Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2024 08:00 ET | Source: Bavarian Nordic A/S

Canada's Only Single-Dose Cholera Vaccine Available Nationwide

Bavarian Nordic announces availability of VAXCHORA, Canada's only single-dose cholera vaccine for travelers (age 2 to 64) to cholera-affected countries.
January 31, 2020 09:26 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency

GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
June 04, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement...
May 20, 2019 16:05 ET | Source: Emergent Biosolutions, Inc.

A Emergent BioSolutions anuncia a concessão de autorização de introdução no mercado em cinco países da UE da sua vacina por via oral contra a febre tifoide; expande a disponibilidade na Europa

GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- A Emergent BioSolutions Inc. (NYSE: EBS) anunciou hoje que foi bem-sucedida na obtenção da autorização de introdução no mercado da sua vacina...
May 20, 2019 16:05 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions gibt Genehmigung der Marktzulassung in fünf EU-Ländern für seinen oralen Typhus-Impfstoff bekannt; Ausweitung der Verfügbarkeit in Europa

GAITHERSBURG, Maryland, May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) gab heute bekannt, dass es erfolgreich die Marktzulassung für seinen oralen Typhus-Impfstoff...
May 20, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine...
April 16, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...